Literature DB >> 23897760

Enrichment of human embryonic stem cell-derived NKX6.1-expressing pancreatic progenitor cells accelerates the maturation of insulin-secreting cells in vivo.

Alireza Rezania1, Jennifer E Bruin, Jean Xu, Kavitha Narayan, Jessica K Fox, John J O'Neil, Timothy J Kieffer.   

Abstract

Human embryonic stem cells (hESCs) are considered a potential alternative to cadaveric islets as a source of transplantable cells for treating patients with diabetes. We previously described a differentiation protocol to generate pancreatic progenitor cells from hESCs, composed of mainly pancreatic endoderm (PDX1/NKX6.1-positive), endocrine precursors (NKX2.2/synaptophysin-positive, hormone/NKX6.1-negative), and polyhormonal cells (insulin/glucagon-positive, NKX6.1-negative). However, the relative contributions of NKX6.1-negative versus NKX6.1-positive cell fractions to the maturation of functional β-cells remained unclear. To address this question, we generated two distinct pancreatic progenitor cell populations using modified differentiation protocols. Prior to transplant, both populations contained a high proportion of PDX1-expressing cells (~85%-90%) but were distinguished by their relatively high (~80%) or low (~25%) expression of NKX6.1. NKX6.1-high and NKX6.1-low progenitor populations were transplanted subcutaneously within macroencapsulation devices into diabetic mice. Mice transplanted with NKX6.1-low cells remained hyperglycemic throughout the 5-month post-transplant period whereas diabetes was reversed in NKX6.1-high recipients within 3 months. Fasting human C-peptide levels were similar between groups throughout the study, but only NKX6.1-high grafts displayed robust meal-, glucose- and arginine-responsive insulin secretion as early as 3 months post-transplant. NKX6.1-low recipients displayed elevated fasting glucagon levels. Theracyte devices from both groups contained almost exclusively pancreatic endocrine tissue, but NKX6.1-high grafts contained a greater proportion of insulin-positive and somatostatin-positive cells, whereas NKX6.1-low grafts contained mainly glucagon-expressing cells. Insulin-positive cells in NKX6.1-high, but not NKX6.1-low grafts expressed nuclear MAFA. Collectively, this study demonstrates that a pancreatic endoderm-enriched population can mature into highly functional β-cells with only a minor contribution from the endocrine subpopulation. © AlphaMed Press.

Entities:  

Keywords:  Beta cells; Cell therapy; Diabetes; Human embryonic stem cells; Transplantation

Mesh:

Substances:

Year:  2013        PMID: 23897760     DOI: 10.1002/stem.1489

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  100 in total

1.  Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement.

Authors:  Stephen T Bartlett; James F Markmann; Paul Johnson; Olle Korsgren; Bernhard J Hering; David Scharp; Thomas W H Kay; Jonathan Bromberg; Jon S Odorico; Gordon C Weir; Nancy Bridges; Raja Kandaswamy; Peter Stock; Peter Friend; Mitsukazu Gotoh; David K C Cooper; Chung-Gyu Park; Phillip OʼConnell; Cherie Stabler; Shinichi Matsumoto; Barbara Ludwig; Pratik Choudhary; Boris Kovatchev; Michael R Rickels; Megan Sykes; Kathryn Wood; Kristy Kraemer; Albert Hwa; Edward Stanley; Camillo Ricordi; Mark Zimmerman; Julia Greenstein; Eduard Montanya; Timo Otonkoski
Journal:  Transplantation       Date:  2016-02       Impact factor: 4.939

Review 2.  Pancreas development in humans.

Authors:  Fong Cheng Pan; Marcela Brissova
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-04       Impact factor: 3.243

3.  Simply the right time to turn on insulin.

Authors:  Francesca M Spagnoli
Journal:  EMBO J       Date:  2015-05-13       Impact factor: 11.598

Review 4.  Advances and challenges in the differentiation of pluripotent stem cells into pancreatic β cells.

Authors:  Essam M Abdelalim; Mohamed M Emara
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

Review 5.  The quest of cell surface markers for stem cell therapy.

Authors:  Anna Meyfour; Sara Pahlavan; Mehdi Mirzaei; Jeroen Krijgsveld; Hossein Baharvand; Ghasem Hosseini Salekdeh
Journal:  Cell Mol Life Sci       Date:  2020-07-24       Impact factor: 9.261

Review 6.  Concise Review: Manufacturing of Pancreatic Endoderm Cells for Clinical Trials in Type 1 Diabetes.

Authors:  Thomas C Schulz
Journal:  Stem Cells Transl Med       Date:  2015-06-10       Impact factor: 6.940

7.  V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A Synthetic Modified mRNA Drives Reprogramming of Human Pancreatic Duct-Derived Cells Into Insulin-Secreting Cells.

Authors:  Elisa Corritore; Yong-Syu Lee; Valentina Pasquale; Daniela Liberati; Mei-Ju Hsu; Catherine Anne Lombard; Patrick Van Der Smissen; Amedeo Vetere; Susan Bonner-Weir; Lorenzo Piemonti; Etienne Sokal; Philippe A Lysy
Journal:  Stem Cells Transl Med       Date:  2016-07-12       Impact factor: 6.940

8.  Retinoic acid plays an evolutionarily conserved and biphasic role in pancreas development.

Authors:  Wei Huang; Guangliang Wang; Fabien Delaspre; Maria Del Carmen Vitery; Rebecca L Beer; Michael J Parsons
Journal:  Dev Biol       Date:  2014-08-13       Impact factor: 3.582

Review 9.  Cell Therapy for Type 1 Diabetes: Current and Future Strategies.

Authors:  Yasaman Aghazadeh; Maria Cristina Nostro
Journal:  Curr Diab Rep       Date:  2017-06       Impact factor: 4.810

10.  Overexpression of PAX4 reduces glucagon expression in differentiating hESCs.

Authors:  Blair K Gage; Robert K Baker; Timothy J Kieffer
Journal:  Islets       Date:  2014       Impact factor: 2.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.